Muraoka Kentaro, Takeya Daiki, Nishimura Kazuhiro, Honda Seiichiro, Numata Yasuhiro, Kobayashi Kota, Jikuya Ryosuke, Tatenuma Tomoyuki, Noguchi Go, Ueno Daiki, Komeya Mitsuru, Ito Hiroki, Ito Yusuke, Hasumi Hisashi, Makiyama Kazuhide
Department of Urology, Yokohama City University Hospital, Kanazawa-ku, Yokohama, Kanagawa, Japan.
Int J Urol. 2025 Jun 19. doi: 10.1111/iju.70156.
To compare complications, perioperative outcomes, postoperative renal function, and recurrence-free survival (RFS) between robot-assisted partial nephrectomy (RAPN) for hilar and non-hilar tumors.
We retrospectively analyzed the medical records of patients who underwent RAPN between March 2016 and August 2023. Patient demographic characteristics were adjusted using 1:1 propensity score matching.
A total of 618 patients (524 with non-hilar tumors and 94 with hilar tumors) were analyzed. Hilar tumors exhibited a larger tumor size, higher RENAL nephrometry score (RNS), and greater complexity than non-hilar tumors pre-matching (all p < 0.05). Propensity score matching resulted in 77 patients per group, with no significant baseline differences except for the L factor of the RNS. Before propensity score matching, hilar tumors were associated with a higher frequency of renal artery/vein clamping and intraperitoneal approaches, as well as significantly longer operative and warm ischemia times than non-hilar tumors. However, after matching, these differences were no longer significant. The adverse event rate was not significantly different between the hilar and non-hilar tumor groups. Trifecta achievement rates were significantly lower in hilar tumors before matching (p < 0.001) but were comparable after matching (p = 0.325). No significant differences were observed in the postoperative eGFR, preservation at 1, 3, and 12 months, or pentafecta rates. Before matching, RFS was significantly lower in hilar tumors (p = 0.015); however, this difference was not significant after matching (p = 0.186).
Hilar tumors showed similar complications, renal function, and recurrence-free survival rates as non-hilar tumors, indicating that RAPN is safe and feasible for hilar tumors.
比较机器人辅助肾部分切除术(RAPN)治疗肾门部肿瘤与非肾门部肿瘤的并发症、围手术期结局、术后肾功能及无复发生存率(RFS)。
我们回顾性分析了2016年3月至2023年8月期间接受RAPN治疗的患者的病历。使用1:1倾向评分匹配对患者的人口统计学特征进行调整。
共分析了618例患者(524例非肾门部肿瘤患者和94例肾门部肿瘤患者)。匹配前,肾门部肿瘤的肿瘤大小更大、RENAL肾计量评分(RNS)更高且比非肾门部肿瘤更复杂(所有p<0.05)。倾向评分匹配后每组有77例患者,除RNS的L因子外,基线无显著差异。在倾向评分匹配前,肾门部肿瘤与肾动脉/静脉夹闭及经腹腔入路的频率更高相关,且手术和热缺血时间明显长于非肾门部肿瘤。然而,匹配后,这些差异不再显著。肾门部和非肾门部肿瘤组的不良事件发生率无显著差异。匹配前肾门部肿瘤的三联成功达成率显著较低(p<0.001),但匹配后相当(p=0.325)。术后估算肾小球滤过率(eGFR)、1个月、3个月和12个月时的肾功能保留情况或五联成功达成率均未观察到显著差异。匹配前,肾门部肿瘤的RFS显著较低(p=0.015);然而,匹配后这种差异不显著(p=0.186)。
肾门部肿瘤与非肾门部肿瘤的并发症、肾功能及无复发生存率相似,表明RAPN治疗肾门部肿瘤是安全可行的。